scPharmaceuticals SCPH 深 沪
已收盘 08-01 16:00:00 美东时间
5.17
+0.090
+1.77%
华盛通- 最 高5.28
- 今 开5.01
- 成交量 39.61万股
- 最 低 4.96
- 昨 收 5.08
- 总市值 2.73亿
- 52周最高 6.2799
- 市盈率 静 --
- 换手率 0.75%
- 52周最低 1.94
- 委 比 64.47%
- 总股本 5279.20万
- 历史最高 18.17
- 量 比 1.61
- 振 幅 6.30%
- 历史最低 1.94
- 每 手 1
- 风险率 0.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025
scPharmaceuticals Inc. has scheduled a conference call and webcast on August 7, 2025, at 4:30 p.m. ET, to discuss its second-quarter 2025 financial results and provide a business update. Participants can join via phone or webcast using the provided links and passcode 4965353. The live webcast and replay will also be accessible on the company’s website. scPharmaceuticals, headquartered in Burlington, MA, focuses on cardiorenal care innovations.
07-31 20:01
scPharmaceuticals shares are trading higher after the company reported better-than-expected Q1 sales results.
scPharmaceuticals shares are trading higher after the company reported better-t...
05-15 22:32
scPharmaceuticals Q1 EPS $(0.37) Misses $(0.30) Estimate, Sales $11.75M Beat $11.63M Estimate
scPharmaceuticals (NASDAQ:SCPH) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 2.78 percent decrease over losses of $(0.36) per share
05-15 04:04
快讯 | scPharmaceuticals 2023年第一季度营业费用为2950.9万美元
ScPharmaceuticals Q1 Operating Expenses USD 29.509 Million
05-15 04:01
快讯 | scPharmaceuticals第一季度营业收入美元指数1175.2万， vs. IBES预估美元指数1160万
ScPharmaceuticals Q1 Revenue USD 11.752 Million Vs. IBES Estimate USD 11.6 Mill...
05-15 04:01
Earnings Scheduled For May 14, 2025
Companies Reporting Before The Bell • Cellebrite DI (NASDAQ:CLBT) is expected t...
05-14 16:32
Insights Ahead: scPharmaceuticals's Quarterly Earnings
scPharmaceuticals (NASDAQ:SCPH) is gearing up to announce its quarterly earning...
05-14 03:04
美股大行评级 | Piper Sandler：上调ACV Auctions, Inc. Class A评级至"超配"，目标价从18美元升至20美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1109762517053050881.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Femasys Inc Ordinary Shares(FEMY)"买入"评级，目标价从12美元升至15美元</p> <p>• Chardan Capital：维持Pri
03-21 09:11
Analyst Expectations For scPharmaceuticals's Future
In the preceding three months, 4 analysts have released ratings for scPharmaceu...
03-21 04:00
ScPharmaceuticals outlines FUROSCIX expansion strategy with CKD launch in April 2025
Earnings Call Insights: scPharmaceuticals (SCPH) Q4 2024 Management View CEO John Tucker highlighted FUROSCIX's Q4 2024 net revenue of $12.2 million, which aligns with the previously announced range o...
03-20 07:14
